Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17151404 | 0.97 | FDPS (0.47) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL5324872 | 0.88 | FDPS (0.56) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL2268534 | 0.84 | FDPS (0.60) | FDPSBLMTDP1BTN3A1CA4 | |
| SCHEMBL1576918 | 0.84 | — | — | |
| Triphosphate SCHEMBL18714 | 0.84 | FDPS (0.69) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL15555988 | 0.84 | FDPS (0.69) | FDPSBLMTDP1BTN3A1CA4 | |
| Ammonia Solution, Strong SCHEMBL28469851 | 0.81 | FDPS (0.56) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL25284822 | 0.81 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL11149492 | 0.81 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL9632051 | 0.81 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024215515-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| CN-111909014-A | Hydroformylation method and catalyst for preparing isononanal from diisobutylene | 惠州凯特立斯科技有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-1063630-C | Surface modified anticancer nanoparticles | NANNO SYSTEM CO (US) | 2001-03-28 | — | — | CN | claimed |
| EP-4345058-B1 | METHOD FOR RECYCLING ORGANOPHOSPHATES | UNIV DRESDEN TECH (DE) | 2026-02-18 | — | — | EP | disclosed |
| EP-4433419-B1 | LIGAND-ASSISTED DEOXYGENATION OF PHOSPHATES TO NITROGENOUS PHOSPHOROUS (V) PRECURSORS AND THEIR CONVERSION TO VARIOUS OXYPHOSPHORUS COMPOUNDS | UNIV DRESDEN TECH (DE) | 2026-02-18 | — | — | EP | disclosed |
| EP-4651906-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES | Ambrx, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4598586-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | Ambrx, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4599083-A1 | SINGLE MOLECULE MULTI-MOLECULAR TRACE METHODS AND SYSTEMS | F. Hoffmann-La Roche AG (CH) | 2025-08-13 | — | — | EP | disclosed |
| US-20250231172-A1 | SINGLE MOLECULE MULTI-MOLECULAR TRACE METHODS AND SYSTEMS | ROCHE SEQUENCING SOLUTIONS INC (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025137293-A2 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | Roche Sequencing Solutions, Inc. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119662650-A | RNAi agents for inhibiting alpha-ENaC expression and methods of use | 箭头药业股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| CN-101422614-A | Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof | JOLLA PHARMA (US) | 2009-05-06 | — | — | CN | disclosed |
| CN-1511041-A | Methods of treating antibody-mediated pathologies using agents that inhibit CD21 | ������ҩ������˾ | 2004-07-07 | — | — | CN | disclosed |
| EP-1185276-B1 | ISOPHOSPHORAMIDE MUSTARD ANALOGS AND USE THEREOF | SOUTHERN RES INST (US) | 2003-12-10 | — | — | EP | disclosed |
| CN-1399562-A | Methods for treating lupus based on antibody affinity and screening methods and compositions using such methods | JOLLA PHARMA (US) | 2003-02-26 | — | — | CN | disclosed |
| CN-1063630-C | Surface modified anticancer nanoparticles | NANNO SYSTEM CO (US) | 2001-03-28 | — | — | CN | disclosed |
| CN-1084391-A | The anticancer granule of receiving of surfaction | STERLING WINTHROP INC (US) | 1994-03-30 | — | — | CN | disclosed |
| US-4956163-A | REACTING A PYROPHOSPHATE ION AND A SULFAMIDE | MONSANTO COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| US-4946662-A | REACTING SULFAMIDES AND PHOSPHATE IONS IN PH BETWEEN 8 AND 10 | MONSANTO COMPANY (US) | 1990-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | FDPS 475/4885BLM 806/4885TDP1 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.